AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) Short Interest Up 661.7% in December

by · The Cerbat Gem

AIM ImmunoTech Inc. (NYSEAMERICAN:AIM – Get Free Report) was the target of a large growth in short interest in December. As of December 31st, there was short interest totaling 205,893 shares, a growth of 661.7% from the December 15th total of 27,032 shares. Based on an average daily volume of 243,723 shares, the short-interest ratio is currently 0.8 days. Currently, 7.2% of the company’s stock are sold short. Currently, 7.2% of the company’s stock are sold short. Based on an average daily volume of 243,723 shares, the short-interest ratio is currently 0.8 days.

Institutional Investors Weigh In On AIM ImmunoTech

An institutional investor recently bought a new position in AIM ImmunoTech stock. Corient Private Wealth LLC acquired a new position in shares of AIM ImmunoTech Inc. (NYSEAMERICAN:AIM – Free Report) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 10,001 shares of the company’s stock, valued at approximately $87,000. Corient Private Wealth LLC owned about 0.37% of AIM ImmunoTech at the end of the most recent reporting period. Hedge funds and other institutional investors own 12.02% of the company’s stock.

AIM ImmunoTech Stock Performance

AIM ImmunoTech stock traded down $0.04 during midday trading on Monday, reaching $1.25. The stock had a trading volume of 71,284 shares, compared to its average volume of 161,428. The stock has a market capitalization of $3.56 million, a P/E ratio of -0.06 and a beta of 1.21. The firm’s fifty day simple moving average is $1.40 and its 200-day simple moving average is $3.14. AIM ImmunoTech has a 1-year low of $1.07 and a 1-year high of $36.00.

AIM ImmunoTech (NYSEAMERICAN:AIM – Get Free Report) last issued its quarterly earnings results on Monday, November 17th. The company reported ($1.57) earnings per share for the quarter. The firm had revenue of $0.03 million for the quarter. On average, sell-side analysts anticipate that AIM ImmunoTech will post -0.3 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Zacks Research raised AIM ImmunoTech from a “hold” rating to a “strong-buy” rating in a research note on Thursday. Two research analysts have rated the stock with a Strong Buy rating, According to data from MarketBeat, AIM ImmunoTech currently has an average rating of “Strong Buy”.

View Our Latest Research Report on AIM ImmunoTech

AIM ImmunoTech Company Profile

(Get Free Report)

AIM ImmunoTech is a clinical-stage biotechnology company focused on the development and commercialization of immune-modulating therapies for the treatment of viral infections and cancer. The company’s lead product candidate, Ampligen (rintatolimod), is a proprietary toll-like receptor 3 (TLR3) agonist that aims to enhance the body’s innate immune response. AIM ImmunoTech’s research and development efforts center on demonstrating the safety and efficacy of Ampligen as both a standalone therapy and in combination with other treatments.

In addition to its oncology and antiviral programs, the company is advancing clinical trials of Ampligen in patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) and exploring potential applications for emerging viral threats.

Further Reading